I have long asserted that it is a market of stocks and not a stock market. Perhaps the veracity of that statement has never been clearer than it is today. We are all aware of the devastation to the stock market in general that the shutdown instigated by the coronavirus has cost. However, despite the general stock market fallout, an article in MarketWatch on April 1, 2020 featured 30 S&P 500 stocks that rose during the disastrous 1st quarter. The following FAST Graphs portfolio review lists those 30 stocks in order of lowest to highest valuation based on adjusted operating earnings P/E ratios.
Summary and Conclusions
This will be the first in a series of videos where I will reveal a cursory overview of these 30 risers that have gone against the grain. With this first video I went from lowest valuations to highest valuations. In part 2 and part 3 I will be going up the valuation chain. In other words, the companies in part 2 will be comprised of companies with higher valuations, as will part 3. To be clear, none of these have been comprehensively researched. They are simply offered to provide a perspective of how vastly different individual stocks that comprise the market are, and how differently they perform even in a crisis like this.
FAST Graphs Analyze Out Loud Reviewing Biogen (BIIB), AmerisourceBergen (ABC), Gilead Sciences (GILD), Davita (DVA), JM Smucker (SJM), Progressive (PGR), Kellogg (K), T Mobile (TMUS), Regeneron (REGN), Akamai (AKAM)
Disclosure: Long ABC, SJM
Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.